- Home
- CABO vs AKRO Comparison
CABO vs AKRO Comparison
Compare CABO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABO
- AKRO
- Stock Information
- Founded
- CABO 1980
- AKRO 2017
- Country
- CABO United States
- AKRO United States
- Employees
- CABO N/A
- AKRO N/A
- Industry
- CABO Cable & Other Pay Television Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CABO Telecommunications
- AKRO Health Care
- Exchange
- CABO Nasdaq
- AKRO Nasdaq
- Market Cap
- CABO 2.0B
- AKRO 2.1B
- IPO Year
- CABO N/A
- AKRO 2019
- Fundamental
- Price
- CABO $342.36
- AKRO $31.59
- Analyst Decision
- CABO Hold
- AKRO Strong Buy
- Analyst Count
- CABO 5
- AKRO 7
- Target Price
- CABO $556.40
- AKRO $43.20
- AVG Volume (30 Days)
- CABO 75.9K
- AKRO 441.5K
- Earning Date
- CABO 11-07-2024
- AKRO 11-11-2024
- Dividend Yield
- CABO 3.55%
- AKRO N/A
- EPS Growth
- CABO 225.28
- AKRO N/A
- EPS
- CABO 35.76
- AKRO N/A
- Revenue
- CABO $1,630,937,000.00
- AKRO N/A
- Revenue This Year
- CABO N/A
- AKRO N/A
- Revenue Next Year
- CABO N/A
- AKRO N/A
- P/E Ratio
- CABO $9.30
- AKRO N/A
- Revenue Growth
- CABO N/A
- AKRO N/A
- 52 Week Low
- CABO $311.28
- AKRO $11.36
- 52 Week High
- CABO $618.44
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- CABO 45.61
- AKRO 66.34
- Support Level
- CABO $330.90
- AKRO $29.34
- Resistance Level
- CABO $350.65
- AKRO $32.15
- Average True Range (ATR)
- CABO 10.83
- AKRO 1.26
- MACD
- CABO -0.56
- AKRO 0.10
- Stochastic Oscillator
- CABO 19.18
- AKRO 99.74
About CABO Cable One Inc.
Cable One Inc is a telecommunications company. It derives revenue from the provision of broadband, voice, and video services to residential and business customers. From a product perspective, the majority of revenue is sourced from data and video services. This revenue is subscription-based and billed monthly. The company also offers Sparklight TV, an internet protocol-based (IPTV) video service that allows customers with Sparklight TV app to stream video channels from the cloud. The company also derives advertising revenue from selling airtime on its video channels. Voice services are offered over Internet protocols. The company owns a telecommunications infrastructure.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.